HCM.LSE HUTCHMED China Ltd

Healthcare Pharmaceuticals London Exchange
2.04 GBX
Close of Nov 3, 2026
150.48 239.00
Market cap
GBX 1.77B
P/E
204.0x
P/B
1.85x
ROE
37.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is HCM.LSE undervalued?

Graham number

The Graham number of HUTCHMED China Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

HUTCHMED China Ltd fundamental analysis

No fundamental analysis for HUTCHMED China Ltd yet.

HUTCHMED China Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About HUTCHMED China Ltd

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), …

Full company profile